ProBiotix Inc, a Maryland research and development corporation established in 1995, develops therapeutic drugs (treatment modalities) and diagnostic kits for neonatal diseases. It maintains critical links with specialists in infectious diseases, gastroenterology, and clinical chemistry, and consequently, with this as a second major strength, ProBiotix aims at developing novel anti-infective agents. A recent graduate from the incubator laboratories in the Bard Life Sciences Building (under the Baltimore Development Corporation), ProBiotix is now poised to launch major pre-clinical and clinical trials of our products.

Recent health care reform has placed formidable demands on the medical community to provide care of similar or better standard at reduced cost. The products that ProBiotix is committed to develop are designed with the aim of preventing diseases and reducing early and late complications that develop as a result of conventional treatment modalities, thereby reducing morbidity, mortality, and, above all, total health care costs.

Capitalization and Partnership Interests
ProBiotix has supported the research and development endeavors with its own private capital, and with additional funding from various Federal and State agencies. Two Phase 1 STTR and one Phase 1 SBIR grants from the National Institutes of Health, and two more awards from Maryland Industrial Partnerships helped to expedite the research and development efforts in these areas during the last two years. We have been contacted by multiple investment companies for taking our products to next phases of development. We are close to filing INDs and move quickly to Phase I clinical trials with corporate partnership/venture capital investment and/or Phase II STTR/SBIR funding.

Scientific Collaborations
The products described herein are being developed in active collaboration with university professors, who are national leaders in the respective areas of research. Estrial is the result of several years of research and is backed by relevant milestone scientific publications. ProBiotix plans to continue the involvement of these university faculty members.